This study was designed to comprehensively analyze the benefit effect and underlying mechanism of egg yolk-derived peptide VPF (Val-Pro-Phe) in bone development by integrating network pharmacology, molecular docking/dynamics simulation, and zebrafish in vivo experiments. Results demonstrated that VPF exhibited dose-dependent intervention effects within the concentration range of 0.2–10 μg/mL in normal and bone dysplasia zebrafish. Specifically, 0.2 μg/mL of VPF exhibited significant enhancements in total length (TL), mineralization, and swimming distance by 4.01%, 14.00% (P < 0.05), and 7.31% in normal zebrafish model, whereas 1 μg/mL of VPF led to significant increases in the aforementioned indexes by 6.30%, 45.26%, and 51.05% (P < 0.05) in bone dysplasia zebrafish model. Then, network pharmacology revealed that the highest correlation between VPF in improving bone development and osteoclast differentiation pathway, with osteoprotegerin (OPG) being the core node in this pathway. Molecular docking results showed that VPF exhibited the highest binding affinity for OPG, and this interaction was further validated by 200 ns molecular dynamics simulations, which demonstrated the stability of the VPF-OPG complex. Furthermore, VPF upregulated the gene expression of OPG, and downregulated the gene expression of the receptor activator of the NF-κB ligand (RANKL) and TNF receptor-associated factor 6 Gene (TRAF6), and downregulated the RANKL/OPG ratio in zebrafish. These data indicate that VPF alleviates skeletal dysplasia primarily by OPG-mediated suppression of osteoclast differentiation within the OPG/RANKL/RANK axis, thereby supporting its potential value as a functional food ingredient for promoting bone development.
Constipation represents a prevalent gastrointestinal disorder. This study demonstrates that wheat peptides (WP) effectively ameliorate loperamide-induced constipation in mice. Administration of WP orally at 0.5 mg/g body weight led to significant improvements in defecation, small intestinal motility, and the integrity of the intestinal barrier. WP further modulated inflammatory markers and enteric nervous system (ENS) regulators while correcting gut microbiota dysbiosis through restoration of microbial diversity and taxonomic composition. Crucially, colon transcriptomics revealed WP-mediated activation of calcium signaling pathway genes and the acetylcholine receptor gene. RT-qPCR validation confirmed the upregulation of key effectors, including muscarinic acetylcholine receptor Chrm1, inositol trisphosphate receptors (Itpr2/3), and calmodulin-like proteins (Calml3, Calm4). Three-dimensional imaging substantiated WP-induced augmentation of enteric neurons in constipated colons. Collectively, these results indicate that WP alleviates constipation through a multitarget mechanism involving muscarinic receptor activation, potentiation of calcium-dependent signaling, and promotion of enteric nervous system recovery, which collectively restore normal intestinal motility. WP thus emerges as a promising therapeutic candidate for constipation management.